Literature DB >> 28830202

Radiological distribution of brain metastases and its implication for the hippocampus avoidance in whole brain radiotherapy approach.

Yi-Min Han1, Gang Cai1, Wei-Min Chai2, Cheng Xu1, Lu Cao1, Dan Ou1, Jia-Yi Chen1, Youlia M Kirova3.   

Abstract

OBJECTIVE: Hippocampus avoidance in whole brain radiotherapy (HA-WBRT) offers the feasibility of less-impaired cognitive function than conventional WBRT. The study aims to assess the radiological distribution of brain metastases (BMs) with relation to the hippocampus and peri-hippocampus region as defined by the RTOG 0933 for better understanding of margin definition in HA-WBRT treatment planning.
METHODS: Consecutive patients with diagnosis of BM from enhanced MRI between March 2011 and July 2016 were analysed. The pre-treatment T1 weighted, T2 weighted, T2 flair, three-dimensional spoiled gradient axial and contrast-enhanced axial cranial MR images of 226 patients are examined. The closest distances between the edge of hippocampus and the margin of tumours on different planes were measured.
RESULTS: A total of 226 patients with 1080 visible metastatic sites were reviewed. The origin of the primary tumors was in 72.6% lung (n = 164), in 45 cases (19.9%) breast cancer and in 7.5% other malignancies (n = 17). There were 758 (70.2%) lesions situated beyond the tentorium. The median size of single lesion was 13.9 ± 14.7 mm. Impossible, it seems that more of the patients are with only one lesion, to verify. The hippocampus involvement was found in 3.1% (n = 7, 95% CI 0.01-0.05) within 5 mm, 5.7% (n = 13, 95% CI 0.03-0.09) within 10mm and 8.4% (n = 19, 95% CI 0.05-0.12) within 20 mm. In multivariate analysis, the number 6 BM or higher was found to be an independent risk factor for hippocampal involvement (HI) (OR: 5.2, 5.38 and 3.84 in 5, 10 and 20 mm).
CONCLUSION: This radiological study found that the incidence of hippocampus involvement is low in patients with BM. HA-WBRT can be delivered under the context of complete radiological diagnosis after careful delineation, proper margin definition and individual planning optimization. Advances in knowledge: The incidence of HI in patients with initial diagnosis of BM from solid tumours impacts the radiotherapeutic decision. Our radiological data analysed the incidence of HI not only to the conventional 5 mm margin definition, but also expanded to wider margins as 10 and 20 mm from hippocampus, which will help the treatment planning optimization with different technique.

Entities:  

Mesh:

Year:  2017        PMID: 28830202      PMCID: PMC5963386          DOI: 10.1259/bjr.20170099

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  34 in total

1.  Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.

Authors:  Hidefumi Aoyama; Hiroki Shirato; Masao Tago; Keiichi Nakagawa; Tatsuya Toyoda; Kazuo Hatano; Masahiro Kenjyo; Natsuo Oya; Saeko Hirota; Hiroki Shioura; Etsuo Kunieda; Taisuke Inomata; Kazushige Hayakawa; Norio Katoh; Gen Kobashi
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

2.  Real-time pretreatment review limits unacceptable deviations on a cooperative group radiation therapy technique trial: quality assurance results of RTOG 0933.

Authors:  Vinai Gondi; Yunfeng Cui; Minesh P Mehta; Denise Manfredi; Ying Xiao; James M Galvin; Howard Rowley; Wolfgang A Tome
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-01-10       Impact factor: 7.038

3.  Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: safety profile for RTOG 0933.

Authors:  Vinai Gondi; Wolfgang A Tome; James Marsh; Aaron Struck; Amol Ghia; Julius V Turian; Søren M Bentzen; John S Kuo; Deepak Khuntia; Minesh P Mehta
Journal:  Radiother Oncol       Date:  2010-04-12       Impact factor: 6.280

4.  Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.

Authors:  William J Magnuson; Nataniel H Lester-Coll; Abraham J Wu; T Jonathan Yang; Natalie A Lockney; Naamit K Gerber; Kathryn Beal; Arya Amini; Tejas Patil; Brian D Kavanagh; D Ross Camidge; Steven E Braunstein; Lauren C Boreta; Suresh K Balasubramanian; Manmeet S Ahluwalia; Niteshkumar G Rana; Albert Attia; Scott N Gettinger; Joseph N Contessa; James B Yu; Veronica L Chiang
Journal:  J Clin Oncol       Date:  2017-01-23       Impact factor: 44.544

5.  Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial.

Authors:  Paul D Brown; Kurt Jaeckle; Karla V Ballman; Elana Farace; Jane H Cerhan; S Keith Anderson; Xiomara W Carrero; Fred G Barker; Richard Deming; Stuart H Burri; Cynthia Ménard; Caroline Chung; Volker W Stieber; Bruce E Pollock; Evanthia Galanis; Jan C Buckner; Anthony L Asher
Journal:  JAMA       Date:  2016-07-26       Impact factor: 56.272

6.  Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.

Authors:  Nancy U Lin; Véronique Diéras; Devchand Paul; Dominique Lossignol; Christos Christodoulou; Hans-Joachim Stemmler; Henri Roché; Minetta C Liu; Richard Greil; Eva Ciruelos; Sibylle Loibl; Stefania Gori; Andrew Wardley; Denise Yardley; Adam Brufsky; Joanne L Blum; Stephen D Rubin; Bernie Dharan; Klaudia Steplewski; Denise Zembryki; Cristina Oliva; Debasish Roychowdhury; Paolo Paoletti; Eric P Winer
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

7.  Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.

Authors:  Qian Zhang; Jian Chen; Xiaoli Yu; Gang Cai; Zhaozhi Yang; Lu Cao; Chaosu Hu; Xiaomao Guo; Jing Sun; Jiayi Chen
Journal:  Breast Cancer       Date:  2015-08-13       Impact factor: 4.239

8.  Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.

Authors:  Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers
Journal:  Lancet Oncol       Date:  2009-10-02       Impact factor: 41.316

9.  Whole brain radiotherapy for brain metastasis.

Authors:  Emory McTyre; Jacob Scott; Prakash Chinnaiyan
Journal:  Surg Neurol Int       Date:  2013-05-02

10.  Dosimetric evaluation of intensity-modulated radiotherapy, volumetric modulated arc therapy, and helical tomotherapy for hippocampal-avoidance whole brain radiotherapy.

Authors:  Yi Rong; Josh Evans; Meng Xu-Welliver; Cadron Pickett; Guang Jia; Quan Chen; Li Zuo
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

View more
  5 in total

Review 1.  Actual, Personalized Approaches to Preserve Cognitive Functions in Brain Metastases Breast Cancer Patients.

Authors:  Monika Konopka-Filippow; Dominika Hempel; Ewa Sierko
Journal:  Cancers (Basel)       Date:  2022-06-25       Impact factor: 6.575

2.  Evaluation of the Hippocampal Normal Tissue Complication Model in a Prospective Cohort of Low Grade Glioma Patients-An Analysis Within the EORTC 22033 Clinical Trial.

Authors:  Jaap Jaspers; Alejandra Mèndez Romero; Mischa S Hoogeman; Martin van den Bent; Ruud G J Wiggenraad; Martin J B Taphoorn; Danielle B P Eekers; Frank J Lagerwaard; Anna Maria Lucas Calduch; Brigitta G Baumert; Martin Klein
Journal:  Front Oncol       Date:  2019-10-01       Impact factor: 6.244

3.  The Risk of Hippocampal Metastasis and the Associated High-Risk Factors in 411 Patients With Brain Metastases.

Authors:  Peng Xie; Hui Qiao; Huiling Hu; Wenlong Xin; Huanyu Zhang; Ning Lan; Xiaohua Chen; Yan Ma
Journal:  Front Oncol       Date:  2022-02-14       Impact factor: 6.244

Review 4.  Exploring the Biological and Physical Basis of Boron Neutron Capture Therapy (BNCT) as a Promising Treatment Frontier in Breast Cancer.

Authors:  Danushka Seneviratne; Pooja Advani; Daniel M Trifiletti; Saranya Chumsri; Chris J Beltran; Aaron F Bush; Laura A Vallow
Journal:  Cancers (Basel)       Date:  2022-06-18       Impact factor: 6.575

Review 5.  New developments in brain metastases.

Authors:  Anna S Berghoff; Matthias Preusser
Journal:  Ther Adv Neurol Disord       Date:  2018-06-28       Impact factor: 6.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.